Moradian Saeed, Ghasemi Shive, Boutorabi Babak, Sharifian Zakieh, Dastjerdi Fay, Buick Catriona, Lee Charlotte T, Mayo Samantha J, Morita Plinio P, Howell Doris
School of Nursing, Faculty of Health, York University, Toronto, ON, Canada.
Shahid Beheshti, Tehran, Iran.
Cancer Inform. 2023 Jun 5;22:11769351231178587. doi: 10.1177/11769351231178587. eCollection 2023.
Immunotherapy has revolutionized the treatment of many different types of cancer, but it is associated with a myriad of immune-related adverse events (irAEs). Patient-reported outcome (PRO) measures have been identified as valuable tools for continuously collecting patient-centered data and are frequently used in oncology trials. However, few studies still research an ePRO follow-up approach on patients treated with Immunotherapy, potentially reflecting a lack of support services for this population.
The team co-developed a digital platform (V-Care) using ePROs to create a new follow-up pathway for cancer patients receiving immunotherapy. To operationalize the first 3 phases of the CeHRes roadmap, we employed multiple methods that were integrated throughout the development process, rather than being performed in a linear fashion. The teams employed an agile approach in a dynamic and iterative manner, engaging key stakeholders throughout the process.
The development of the application was categorized into 2 phases: "user interface" (UI) and "user experience" (UX) designs. In the first phase, the pages of the application were segmented into general categories, and feedback from all stakeholders was received and used to modify the application. In phase 2, mock-up pages were developed and sent to the Figma website. Moreover, the Android Package Kit (APK) of the application was installed and tested multiple times on a mobile phone to proactively detect and fix any errors. After resolving some technical issues and adjusting errors on the Android version to improve the user experience, the iOS version of the application was developed.
By incorporating the latest technological developments, V-Care has enabled cancer patients to have access to more comprehensive and personalized care, allowing them to better manage their condition and be better informed about their health decisions. These advances have also enabled healthcare professionals to be better equipped with the knowledge and tools to provide more effective and efficient care. In addition, the advances in V-Care technology have allowed patients to connect with their healthcare providers more easily, providing a platform to facilitate communication and collaboration. Although usability testing is necessary to evaluate the efficacy and user experience of the app, it can be a significant investment of time and resources.
The V-Care platform can be used to investigate the reported symptoms experienced by cancer patients receiving Immune checkpoint inhibitors (ICIs) and to compare them with the results from clinical trials. Furthermore, the project will utilize ePRO tools to collect symptoms from patients and provide insight into whether the reported symptoms are linked to the treatment.
V-Care provides a secure, easy-to-use interface for patient-clinician communication and data exchange. Its clinical system stores and manages patient data in a secure environment, while its clinical decision support system helps clinicians make decisions that are more informed, efficient, and cost-effective. This system has the potential to improve patient safety and quality of care, while also helping to reduce healthcare costs.
免疫疗法彻底改变了许多不同类型癌症的治疗方式,但它与众多免疫相关不良事件(irAEs)相关。患者报告结局(PRO)指标已被确认为持续收集以患者为中心的数据的宝贵工具,并经常用于肿瘤学试验。然而,仍很少有研究对接受免疫疗法治疗的患者采用电子PRO随访方法,这可能反映出该人群缺乏支持服务。
该团队共同开发了一个使用电子PRO的数字平台(V-Care),为接受免疫疗法的癌症患者创建了一条新的随访途径。为实施CeHRes路线图的前三个阶段,我们采用了多种方法,这些方法在整个开发过程中相互整合,而非以线性方式执行。团队以动态和迭代的方式采用敏捷方法,在整个过程中让关键利益相关者参与进来。
该应用程序的开发分为两个阶段:“用户界面”(UI)和“用户体验”(UX)设计。在第一阶段,应用程序的页面被分成一般类别,并收集了所有利益相关者的反馈并用于修改应用程序。在第二阶段,开发了原型页面并发送到Figma网站。此外,该应用程序的安卓安装包(APK)在手机上多次安装和测试,以主动检测和修复任何错误。在解决了一些技术问题并调整了安卓版本上的错误以改善用户体验后,开发了该应用程序的iOS版本。
通过纳入最新技术发展,V-Care使癌症患者能够获得更全面和个性化的护理,使他们能够更好地管理自己的病情,并在健康决策方面获得更多信息。这些进展还使医疗保健专业人员能够更好地掌握知识和工具,以提供更有效和高效的护理。此外,V-Care技术的进步使患者能够更轻松地与医疗保健提供者联系,提供了一个促进沟通与协作的平台。尽管可用性测试对于评估该应用程序的功效和用户体验是必要的,但这可能是一项重大的时间和资源投资。
V-Care平台可用于调查接受免疫检查点抑制剂(ICI)治疗的癌症患者报告的症状,并将其与临床试验结果进行比较。此外,该项目将利用电子PRO工具收集患者的症状,并深入了解报告的症状是否与治疗有关。
V-Care为患者与临床医生的沟通和数据交换提供了一个安全、易于使用的界面。其临床系统在安全环境中存储和管理患者数据,而其临床决策支持系统帮助临床医生做出更明智、高效和具有成本效益的决策。该系统有可能提高患者安全性和护理质量,同时也有助于降低医疗成本。